Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fazirsiran in Alpha-1 Antitrypsin Deficiency-Associated Liver Disease
NCT05677971Phase 3Recruiting
- Sponsor
- Takeda
- Start
- Mar 2023
- Primary completion
- Jan 2029
- Modality
- Antisense DNA, Conjugated siRNA, MicroRNA (miRNA)
- Countries
- 19
01
Overview
A Phase 3 trial of fazirsiran in alpha-1 antitrypsin deficiency (AATD), sponsored by Takeda. Started Mar 2023; status: recruiting.
02
Drugs
fazirsiran
03
Conditions
alpha-1 antitrypsin deficiency (AATD)
Beyond the preview
Go deeper on NCT05677971.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05677971.